US 11,773,051 B2
S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
Eric Verdin, Mill Valley, CA (US); and John C. Newman, San Francisco, CA (US)
Assigned to Buck Institute for Research on Aging, Novato, CA (US); The Regents of The University Of California, Oakland, CA (US); and The J. David Gladstone Institutes, San Francisco, CA (US)
Appl. No. 16/631,374
Filed by Buck Institute for Research on Aging, Novato, CA (US); The Regents of the University of California, Oakland, CA (US); and The J. David Gladstone Institutes, San Francisco, CA (US)
PCT Filed Jul. 19, 2018, PCT No. PCT/US2018/042948
§ 371(c)(1), (2) Date Jan. 15, 2020,
PCT Pub. No. WO2019/018683, PCT Pub. Date Jan. 24, 2019.
Claims priority of provisional application 62/535,754, filed on Jul. 21, 2017.
Prior Publication US 2020/0140371 A1, May 7, 2020
Int. Cl. C07C 69/675 (2006.01); A23L 29/00 (2016.01); A61P 25/28 (2006.01); A23L 2/38 (2021.01); A61K 9/00 (2006.01)
CPC C07C 69/675 (2013.01) [A23L 2/38 (2013.01); A23L 29/035 (2016.08); A61P 25/28 (2018.01); A61K 9/0056 (2013.01); C07B 2200/07 (2013.01)] 16 Claims
 
1. A method of treating dementia or other neurocognitive disorder, said method comprising administering to a subject in need thereof an effective amount of a composition comprising betahydroxybutyrate-1,3-butanediol enriched for the enantiomer S-BHB-S-1,3-butanediol represented by Formula I:

OG Complex Work Unit Chemistry